This is a 6-week randomized, double-blind trial of 4 different non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis to compare the change of pain score from baseline at 4 weeks to the change of pain score from baseline at 6 weeks.
Name: Indomethacin
Name: Diclofenac
Name: Meloxicam
Name: Celecoxib
Description: Change of pain score by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]
Measure: Change of Pain Score Time: Baseline, Week 4, and Week 6Description: Change of BASDAI by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]
Measure: Change of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Time: Baseline, Week 4, and Week 6Description: Change of BASFI by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]
Measure: Change of Bath Ankylosing Spondylitis Function Index (BASFI) Time: Baseline, Week 4, and Week 6Description: Change of ASDAS by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]
Measure: Change of ASAS Endorsed Disease Activity Score (ASDAS) Time: Baseline, Week 4, and Week 6Description: Likert Scale on whether effective or not.
Measure: Patient Global Assessment of Response to Therapy (PGART) Time: Week 6Allocation: Randomized
Parallel Assignment
There is one SNP
Ankylosing Spondylitis Axial Spondyloarthritis Spondylitis Spondylitis, Ankylosing Spondylarthritis Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion and exclusion criteria will be randomized into one of the four arms after an initial one week washout period, including: 1) indomethacin 75mg every 12 hours (Q12H); 2) diclofenac 75mg Q12H; 3) meloxicam 7.5mg Q12H; 4) celecoxib 200mg Q12H. --- Q12H ---
Ankylosing Spondylitis Axial Spondyloarthritis Spondylitis Spondylitis, Ankylosing Spondylarthritis Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion and exclusion criteria will be randomized into one of the four arms after an initial one week washout period, including: 1) indomethacin 75mg every 12 hours (Q12H); 2) diclofenac 75mg Q12H; 3) meloxicam 7.5mg Q12H; 4) celecoxib 200mg Q12H. --- Q12H --- --- Q12H ---
Ankylosing Spondylitis Axial Spondyloarthritis Spondylitis Spondylitis, Ankylosing Spondylarthritis Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion and exclusion criteria will be randomized into one of the four arms after an initial one week washout period, including: 1) indomethacin 75mg every 12 hours (Q12H); 2) diclofenac 75mg Q12H; 3) meloxicam 7.5mg Q12H; 4) celecoxib 200mg Q12H. --- Q12H --- --- Q12H --- --- Q12H ---
Ankylosing Spondylitis Axial Spondyloarthritis Spondylitis Spondylitis, Ankylosing Spondylarthritis Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion and exclusion criteria will be randomized into one of the four arms after an initial one week washout period, including: 1) indomethacin 75mg every 12 hours (Q12H); 2) diclofenac 75mg Q12H; 3) meloxicam 7.5mg Q12H; 4) celecoxib 200mg Q12H. --- Q12H --- --- Q12H --- --- Q12H --- --- Q12H ---